Neos Therapeutics Inc. (NASDAQ:NEOS) rose 3.5% on Tuesday . The company traded as high as $6.83 and last traded at $6.83, with a volume of 113,952 shares. The stock had previously closed at $6.60.

NEOS has been the subject of a number of research analyst reports. Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. BMO Capital Markets began coverage on Neos Therapeutics in a research report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price objective for the company. Zacks Investment Research lowered Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Finally, Royal Bank Of Canada reduced their target price on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $21.75.

The firm’s 50 day moving average is $8.05 and its 200-day moving average is $9.37. The company’s market capitalization is $104.78 million.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.49. The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, equities analysts forecast that Neos Therapeutics Inc. will post ($5.38) EPS for the current year.

In related news, insider Juergen Martens acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The shares were acquired at an average cost of $9.90 per share, with a total value of $99,000.00. Following the transaction, the insider now owns 10,000 shares of the company’s stock, valued at approximately $99,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Richard I. Eisenstadt acquired 3,710 shares of the business’s stock in a transaction that occurred on Thursday, August 25th. The stock was bought at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the completion of the transaction, the chief financial officer now directly owns 3,710 shares in the company, valued at approximately $25,302.20. The disclosure for this purchase can be found here.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).